MTS 004
Alternative Names: MTS 004 ODT; MTS‑004Latest Information Update: 28 Jan 2026
At a glance
- Originator METiS Pharmaceuticals
- Developer METiS TechBio
- Class Behavioural disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Emotional lability
- Preclinical Deglutition disorders
Most Recent Events
- 12 Jan 2026 Preclinical trials in Deglutition disorders in China (PO) (METiS TechBio pipeline, January 2026)
- 05 Nov 2025 Efficacy and adverse events data from a phase III trial in Emotional lability released by METiS Pharmaceuticals
- 23 Oct 2025 METiS Pharmaceuticals plans to submit a New Drug Application (NDA) for MTS 004 to the National Medical Products Administration (NMPA) in Emotional lability in 2026